Eli Lilly and Company wins FDA pediatric Olumiant approval for severe alopecia

{
  "signal_id": "e2e90d18-d036-1d08-6b1d-9bdf5fee5c6e",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-25T23:27:05+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://mugglehead.com/eli-lilly-olumiant-pediatric-severe-alopecia-fda-approval/",
    "title": "Eli Lilly and Company wins FDA pediatric Olumiant approval for severe alopecia - Mugglehead Investment Magazine",
    "excerpt": "A new U.S. treatment option for adolescents with severe alopecia areata opened Friday after the Food and Drug Administration expanded the Olumiant label for Eli Lilly and Company NYSE LLY to patients aged 12 and older. In the pivotal trial, 42 per cent on the higher dose reached the scalp hair endpoint at 36 weeks, against 5 per cent on placebo. The September 2026 prescribing label recommends 2 mg once daily, with an increase to 4 mg if response is inadequate. It says clinicians should consider starting at 4 mg when scalp hair loss is nearly complete or complete, then reduce the dose after an adequate response. Lilly is a large-cap Indianapolis drugmaker that sells prescription medicines in the United States and overseas. Lilly's NYSE LLY quote showed shares at US$1,183.46 as of 4:03 p.m. EDT on Sept. 25. That quote preceded the after-hours announcement, so Friday's regular-session change does not measure investors' response to the approval. BRAVE-AA-PEDS randomized 257 adolescents among placebo and two active-dose arms, Lilly said in its Sept. 25 release. Participants were aged 12 to under 18, and the active doses were 2 mg and 4 mg. The primary endpoint was a Severity of Alopecia Tool score of 20 or less at Week 36, meaning at least 80 per cent scalp hair coverage. The median score at entry was 100, indicating complete scalp hair loss. The lower-dose group reached that...",
    "product": "Olumiant",
    "summary": "The U.S. Food and Drug Administration (FDA) has approved an expanded label for Eli Lilly's drug Olumiant, making it a treatment option for adolescents aged 12 and older with severe alopecia areata.",
    "location": "United States",
    "planning": false,
    "image_url": "https://6d2x3bhx55ulp01t.public.blob.vercel-storage.com/images/agent/675c8b390de4.jpg",
    "confidence": 1,
    "product_data": {
      "name": "Olumiant",
      "full_text": "Olumiant label",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-25T23:27:05Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-25",
    "article_sentence": "A new U.S. treatment option for adolescents with severe alopecia areata opened Friday after the Food and Drug Administration expanded the Olumiant label for Eli Lilly and Company NYSE LLY to patients aged 12 and older."
  }
}

curl https://signals.autobound.ai/v1/signals/e2e90d18-d036-1d08-6b1d-9bdf5fee5c6e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'